Japan handles reimbursement for digital health devices through the MHLW & Chuikyo. These devices must demonstrate clinical efficacy, safety, & cost-effectiveness. They are classified under existing categories or evaluated for new classifications. Evidence from clinical trials or real-world data is essential, & reimbursement approval aligns with the NHI framework for coverage.
